Savara (SVRA) Shares Outstanding (Diluted Average) (2021 - 2026)
Savara (SVRA) reported Shares Outstanding (Diluted Average) of $253.3 million for Q1 2026, up 17.18% year-over-year from $216.1 million in Q1 2025, and up 13.89% on a QoQ basis from $222.4 million in Q4 2025.
Savara (SVRA) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $253.3 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) rose 17.18% year-over-year to $253.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $253.3 million (up 17.18% YoY) and the FY2025 annual result came in at $222.4 million, up 12.21% from the prior year.
- Shares Outstanding (Diluted Average) climbed to $253.3 million in Q1 2026 per SVRA's latest filing, from $222.4 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $253.3 million in Q1 2026 and bottomed at $152.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $182.6 million (2024), against an average of $184.5 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) gained 0.01%; it then gained 19.97% in 2024.
- Tracing SVRA's Shares Outstanding (Diluted Average) over 5 years: stood at $152.8 million in 2022, then gained by 8.14% to $165.2 million in 2023, then grew by 19.97% to $198.2 million in 2024, then grew by 12.21% to $222.4 million in 2025, then gained by 13.89% to $253.3 million in 2026.
- Per Business Quant, the three latest SVRA Shares Outstanding (Diluted Average) figures stand at $253.3 million (Q1 2026), $222.4 million (Q4 2025), and $216.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 253.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.28 Mn |
| Dec 31, 2025 | 222.39 Mn |
| Sep 30, 2025 | 216.46 Mn |
| Jun 30, 2025 | 216.29 Mn |
| Mar 31, 2025 | 216.15 Mn |
| Dec 31, 2024 | 198.19 Mn |
| Sep 30, 2024 | 192.40 Mn |
| Jun 30, 2024 | 182.57 Mn |
| Mar 31, 2024 | 182.55 Mn |
| Dec 31, 2023 | 165.20 Mn |
| Sep 30, 2023 | 174.70 Mn |
| Jun 30, 2023 | 152.80 Mn |
| Mar 31, 2023 | 152.78 Mn |
| Dec 31, 2022 | 152.77 Mn |
| Sep 30, 2022 | 152.77 Mn |
| Jun 30, 2022 | 152.77 Mn |
| Mar 31, 2022 | 152.77 Mn |
| Dec 31, 2021 | 133.92 Mn |
| Sep 30, 2021 | 127.62 Mn |
| Jun 30, 2021 | 152.46 Mn |